论文部分内容阅读
目的观察伊立替康(CPT-11)联合顺铂(DDP)治疗初治小细胞肺癌的临床疗效和安全性。方法 34例小细胞肺癌患者,采用CPT-11 65mg/m2,静滴,第1、8天;DDP 25mg/m2,静滴;第1～3d。21d为1个周期,至少完成2个周期后评价疗效和不良反应。结果 34例患者中CR5例,PR21例,总有效率RR76.5%,无进展生存期(PFS)5.4个月。主要毒副反应为血液学毒性和消化道反应,仅3例出现III度腹泻。结论 CPT-11联合DDP一线治疗小细胞肺癌是安全及有效的,毒性可耐受,迟发性腹泻是可以控制的。
Objective To observe the clinical efficacy and safety of irinotecan (CPT-11) combined with cisplatin (DDP) in the treatment of primary small cell lung cancer. Methods Thirty-four patients with small cell lung cancer were treated with CPT-11 65mg / m2 intravenously for days 1 and 8; DDP 25mg / m2 intravenously; 21d for a period of at least 2 cycles after the completion of evaluation of efficacy and adverse reactions. Results Of the 34 patients, 5 were CR and 21 were PR, with a total effective rate of 76.5% and a progression-free survival (PFS) of 5.4 months. The main toxicities were hematological toxicity and gastrointestinal reactions, with only 3 cases of grade III diarrhea. Conclusion CPT-11 combined with DDP first-line treatment of small cell lung cancer is safe and effective, tolerable toxicity, delayed diarrhea can be controlled.